Breaking Free from the Grasp of Seasonal Influenza: Key Diagnostic and Management Considerations on the Front Lines of Care
May 26, 2021
May 26, 2022
Scroll to the Bottom of this Information to Begin this Course
This CME activity is provided by Integrity Continuing Education.
This AANP activity is jointly provided by Global Education Group and Integrity Continuing Education.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurse Practitioner — 1.0 contact hour (which includes 0.5 hours of pharmacology) of AANP credit
All other health care professionals completing this course will be issued a statement of participation.
This educational initiative has been designed for nurse practitioners, physician assistants, and physicians who practice in primary care and specialty settings.
Every year, seasonal influenza is a significant cause of mortality among at-risk populations, elderly individuals, pregnant women, and children under 2 years of age. In light of the coronavirus disease (COVID-19) pandemic, there is wide-spread apprehension regarding effective prevention and management of seasonal influenza during 2021-2022. Concurrent influenza and COVID-19 outbreaks could further critically overwhelm healthcare systems and drain resources, thereby exponentially increasing their burden. Therefore, overcoming existing and new barriers related to the best practice management of influenza is of high priority. Given that nurse practitioners (NPs) and physician assistants (PAs) can aid in reducing influenza-associated morbidity and mortality, it is crucial that these professionals are well-prepared to vaccinate, diagnose, and treat patients that are at risk for developing or have seasonal influenza.
This activity will address knowledge and competence gaps regarding the prevention and management of influenza and ensure that influenza outbreaks are not missed or ignored during the COVID-19 pandemic.
Upon completion of this educational activity, participants should be able to:
- Articulate the role of vaccination in reducing the spread of influenza and improving patient outcomes while emphasizing the importance of vaccination during the COVID-19 pandemic
- Describe how to implement updated guidelines to differentially diagnose influenza in order to initiate early and appropriate therapy
- Discuss how to utilize antiviral chemoprophylaxis in appropriate individuals at high risk of developing influenza and associated complications
- Interpret existing and new evidence with traditional and new influenza treatments, including differences in efficacy and safety, dosage and administration, and reduction in disease burden and complications
- Outline how to individualize flu treatment with antiviral medications among diverse patients
William A. Fischer II, MD
Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Institute of Global Health and Infectious Diseases
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Ryan Holley-Mallo, PhD, DNP, NP-C, FAANP
Associate Professor, Graduate Nursing
Nurse Practitioner in Family Medicine
Catherine's Health Center
Grand Rapids, Michigan
Physician Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Credit Designation
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour (which includes 0.5 hours of pharmacology).
Disclosures of Conflicts of Interest
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
William A. Fischer II, MD
- Research Support: Ridgeback Biopharmaceuticals
- Consultant: Roche and Merck
- Adjudication Panel: Janssen and Syneos
Ryan Holley-Mallo, PhD, DNP, NP-C, FAANP has no real or apparent conflicts of interest to disclose.
The planners and managers, Michelle R. Rizzo, ELS, and Donna Fausak, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. The Global Education Group planners and managers, Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, and Ashley Cann, also have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of May 26, 2021 through May 26, 2022, participants must:
- Read the learning objectives and faculty disclosures.
- Complete the pretest.
- Study the educational activity.
- Complete the posttest and the evaluation form.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education and Global Education Group do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or email@example.com.
For information about AANP accreditation of this activity, please contact Global Education Group at (303) 395-1782 or firstname.lastname@example.org.